Clinical Research

Dr Victoria Galvis’ research is defined by academic rigour, methodological precision, and a commitment to generating evidence that improves real‑world practice. Her work spans clinical inquiry, service evaluation, and interdisciplinary collaboration, with a focus on producing high‑quality research that stands up to peer review and contributes meaningfully to the academic community. Through ongoing studies, publications, and knowledge‑exchange activities, she advances understanding in her field while ensuring that research findings translate into practical, measurable impact for professionals, organisations, and the people they serve.

 

dr victoria galvis projects 1250x852 (1)

Oncological Research:

Dr Victoria Galvis’ research is rooted in improving outcomes and experiences for people affected by cancer. Her work spans clinical practice, service development, and patient‑centred innovation, with a focus on understanding the real‑world challenges faced across the oncology pathway. Through ongoing projects, collaborative studies, and evidence‑based inquiry, she aims to strengthen the quality, safety, and equity of cancer care—ensuring that research translates into meaningful improvements for patients, families, and the professionals who support them.

Journal of Clinical Oncology

Treatment of metastatic renal cancer with high-dose interleukin-2 after targeted therapy.

Authors: Robert E. Hawkins, Victoria Galvis, Jonathan Shanks, Neha Dalal, Fiona Thistlethwaite, and Andrea Spencer-Shaw

High dose Interleukin 2 (HD IL2) as 1st line treatment in metastatic renal cell carcinoma (mRCC): A 10-year single centre experience.

Authors: Shien Chow, Victoria Galvis, Manon Pillai, Rebecca Leach, Elizabeth Keene, Andrea Spencer-Shaw, Liptrot Tom, Jonathan Shanks, Alaaeldin Shablak, Fiona Thistlethwaithe, and Robert E. Hawkins

10 year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC).

Authors: Shien Chow, Manon Rhys Pillai, Victoria Galvis, Rebecca Leach, Elizabeth Keene, Kevin Chan, Andrea Spencer-Shaw, Fiona Thistlethwaithe, and Robert E. Hawkins

Journal for ImmunoTherapy of Cancer

High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) – a 10 year single-site experience and outcome of prospective pathology-based patient selection

  • Published: 

Authors: Shien Chow,  Manon Evans, Victoria Galvis, Rebecca Leach, Elizabeth Keene, Kevin Chan, Andrea Spencer-Shaw, Shanks Jonathan, Alaaeldin Shabalak, Fiona Thistlethwaite & Robert Hawkins